Keywords: abraxis, spins-off, independent, early-stage, drug, development, company
Abraxis spins-off independent early-stage drug development company
Article | 26 January 2009
USA-based Abraxis BioScience is to spin-off an independent company, called Abraxis Health, focused on early-stage drug development. The parent firm ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
